Progression of the cell cycle in eukaryotic cells is strictly and skillfully regulated by the sequential formation, activation, and subsequent inactivation of a series of cyclin and cyclin-dependent kinase (CDK) complexes. The activation of CDK4 and CDK6 by cyclin D elicits phosphorylation of retinoblastoma protein (pRB), which results in release of several pRB-associated transcription factors required for G1 to S phase progression. Among a family of proteins that bind and inhibit CDKs, p16
CDK6 ultimately resulting in inhibition of cell division. The p16 gene located on chromosomal region 9p21 appears to be inactivated in a wide variety of tumors, and mice carrying a targeted deletion of p16 demonstrate development of spontaneous tumors at a high rate, suggesting that p16 could be a tumor suppressor. The human p16 gene locus encodes a second protein p14 ARF via transcription of an alternative first exon and common exon 2 in different reading frame. This protein does not directly bind and inhibit CDKs but appears to enhance the functional activity of wild-type p53. Because mice with disrupted p19 ARF (the mouse homologue of p14 ARF ) but intact p16 expression have a susceptibility to cancer, p14 ARF is considered as another tumor suppressor. Among mechanisms that inactivate p16 in tumor cells, homozygous deletion may predominantly contribute to tumorigenesis or disease progression, because this inactivates both p16 and p14
ARF that act upstream of pathways involving pRB and p53, respectively. However, there are some controversies regarding the sig-nificance of the p16 gene deletion, because the frequencies appear to be much lower in primary tumors than in cell lines. In acute lymphoblastic leukemia (ALL), the reported percentages of homozygous deletion in patients' samples and cell lines are 14-29% and 70%, respectively. [1] [2] [3] There could be two possible explanations for these discrepancies. One is that homozygous deletion of p16 is specifically associated with the biological nature of high grade malignancy, which leads not only to the high rate of relapse and the disease progression in vivo but also to the cell line establishment in vitro. The other is that this genomic loss occurs during the process of cell culture for the cell line establishment, and therefore this transformation in vitro should be called an artifact. To address this, Kees et al 4 examined the p16 gene status in 12 matched pairs of primary leukemia sample and corresponding cell line, and found that the status was identical in each pair, indicating that loss of the p16 gene is not an artifact. In their study, two of four pairs from B-precursor ALL had intact p16 alleles and the other two pairs had homozygous deletion. However, no additional studies on the p16 gene status using pairs of primary leukemia sample and corresponding cell line have been performed. To address the biological and clinical significance of p16 abnormalities in childhood B-precursor ALL without nonrandom translocations, we investigated the p16 gene status in seven matched pairs of primary leukemia and corresponding cell line.
Seven pairs of primary sample and cell line from childhood B-precursor ALL without nonrandom translocations such as 9;22, 11q23-related, and 1;19 translocations were available and used in this study. The patients, all females aged 6 to 13 years (median 10) with peripheral white blood cells ranging from 3.4 to 191.8 × 10 9 /l (median 69.8), were diagnosed to have B-precursor ALL (CD10 Table 1 . Although karyotypic abnormalities that clearly affect the 9p21 region were not revealed in five patient samples examined, they were detected in five of seven cell lines. BM cells from patients 4 and 5 were reported to have normal karyotype, 9) . Southern blot analysis of the p16 gene was next performed using three pairs of diagnostic and relapsed specimens (patients 5-7) and corresponding cell lines (KOPN-40, 47 and 70) as shown in Figure 1c . In patients 5 and 6, homozygous deletion was revealed in diagnostic samples which was consistently detectable in relapsed samples and established cell lines (lanes 2-7) . The diagnostic and relapsed specimens of patient 7 showed hemizygous (lane 8) and homozygous (lane 9) deletions, respectively, suggesting that the retained allele was lost in the interval between onset and relapse. The cell line from patient 7 maintained homozygous deletion (lane 10).
As summarized in Table 1 , abnormalities of the p16 gene were revealed in all of the diagnostic samples; homozygous deletion 4, hemizygous deletion with or without a rearranged allele 2, and no deletion with a rearranged allele 1, although karyotypic analysis did not show abnormalities affecting 9p21 for which difficulty in preparation of well-banded chromosomes from primary samples may partly be responsible. Clinically, six of seven patients relapsed and died early. In the interval between onset and relapse, one patient with hemizygous deletion lost the retained allele as in a report by others. 5 Thus, five of seven cell lines proved to be established from patient samples with homozygous deletion of the p16 gene, while two cell lines proved to lose intact or rearranged allele of p16 in the process of establishment. These findings suggest that abnormalities of the p16 gene, particularly homozygous deletion at the onset of childhood Bprecursor ALL without nonrandom translocations, are closely associated with the refractory nature of the disease to chemotherapy, and that homozygous deletion of the p16 gene frequently observed in leu-
Figure 1
Southern blot analysis of the p16 gene. The procedure is described in our previous report. 6 To confirm the amount and integrity of genomic DNA for each sample, blots were rehybridized with a probe prepared from human CD13 cDNA. The ratio of the signal by the p16 probe to that by the CD13 probe was used to define the presence of homozygous or hemizygous p16 deletion. (a) Restriction map of BglII in the region containing the p15 and p16 genes. Closed boxes indicate exon 2 of p15 and exons 1␣, 2, and 3 of p16 hybridized with a 0.8-kb EcoRI/HincII p16 cDNA probe. Because the p16 cDNA probe used not only hybridizes to genomic fragments including exons 1␣, 2, and 3 of p16 but also cross-hybridizes weakly to the fragment including exon 2 of p15, BglII fragments of 9.4-, 6.6-, 4. Mutation study of the BCL10 gene in lymphoma with both RNA and DNA
TO THE EDITOR
The BCL10 gene has been cloned from the chromosomal translocation t(1;14)(p22;q32) in a low-grade mucosa-associated tissue (MALT) lymphoma. 1 The function of the protein is not yet clear, and it also remains to be proved whether BCL10 is an oncogene or a tumor suppressor gene. 1, 2 Willis et al 1 suggested that BCL10 mRNA exhibited hypermutations in MALT lymphomas with t(1;14), as well as frequent mutations in 45% of B and T cell lineage lymphomas without 1q22 chromosomal rearrangements. In a recent issue of Leukemia, Luminari et al 3 reported, however, that BCL10 mutations are rare, when they examined genomic DNA of various types of lymphoid malignancies. Some BCL10 gene abnormalities were proposed to be found only in RNA and not in genomic DNA, 4, 5 but no previous studies investigated DNA and RNA at the same time. [4] [5] [6] [7] [8] To make the matter clear, we first analyzed the mutations of BCL10 RNA from 43 lymphomas, and for those lymphomas with RNA alterations we investigated the genomic DNA extracted from the same tumor and normal tissues from the same patients.
We amplified the RNA from 11 follicular lymphomas, which are reported to be more frequently involved with BCL10 gene mutations, by reverse transcription PCR (RT-PCR) with two sets of primers covering the full-length cording region of the BCL10 gene, then recovered bands after agarose gel electrophoresis, and sequenced with the direct sequencing method. In one patient a distinct band of a smaller size was detected by agarose gel electrophoresis and ethidium bromide staining of the RT-PCR product, together with a faint band of the expected size, and sequence analysis revealed an 81 base pair deletion (Figure 1 ). This 81 base pair deletion should cause a 27 amino acid in-frame deletion (aa 206-232) at the C-terminal portion of the BCL10 protein. In another patient we found C/T heterozygosity of the second base of codon 162 resulting in the substitution of an amino acid (threonine to methionine). We also studied RNA from these 11 follicular lymphomas and 32 diffuse lymphomas by reverse transcription PCR-SSCP (RT-PCR-SSCP) with four sets of primer pairs covering the full length of the coding region of the BCL10 gene, but detected no more abnormalities except for those mentioned above (data not shown).
For the two follicular lymphoma patients with sequence alterations of BCL10 RNA we investigated the mutations of the DNA samples isolated from the same lymphoma tissue and bone marrow without documented lymphoma invasion by PCR and direct sequencing. In the patient with C/T heterozygosity, identical C/T heterozygosity was detected in both DNA from the same lymphoma sample and that from the bone marrow without lymphoma involvement, thus this single nucleotide substitution may probably be a polymorphism. In the lymphoma of this patient, which is considered to be monoclonal, both C 485 and T 485 alleles (according to numbering described by Willis et al 1 ), appeared to be evenly expressed. This observation may indicate that BCL10 is biallelically expressed, as most genes are. In the patient with an 81 base pair deletion in RNA, the abnormal and normal alleles were detected evenly in the genomic DNA from the same tumor sample, but the mutated allele was not detected in his bone marrow without lymphoma (Figure 1b) . Therefore, this deletion mutation is tumor-specific. Furthermore, as the RNA analysis of the tumor showed that more mutated allele was expressed than normal allele (Figure 1a ), this mutant allele may predominantly be expressed in the lymphoma cells.
BCL10 RNA clones with post-transcriptional sequence modification, which Willis et al 1 and Takahashi et al 8 showed to be frequently found in lymphoma and normal peripheral blood lymphocytes by cDNA cloning method, could not be demonstrated in this study with either RT-PCR SSCP or direct sequencing of RNA. It is suggested that the amount of each RNA clone with post-transcriptional sequence modification may be too small for detection with RT-PCR SSCP or the direct sequencing method. So it is a question whether such a small population of BCL10 RNA has a biological significance on lymphomagenesis. 8 In conclusion, mutations of BCL10 gene may be infrequent in follicular lymphomas and even rarer in diffuse lymphomas. The deletion mutation we found should cause an in-frame deletion at the C-terminal portion of the BCL10 protein, which is similar to the mutations reported in previous studies, 1, 2 confirming that the abnormality of the C-terminal portion is important for lymphomagenesis. Our study revealed that BCL10 gene mutations detected distinctly in RNA by RT-PCR SSCP or direct sequencing were confirmed in genomic DNA,
